All In Biotech

Free tool

FAERS Monitor: Camzyos

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214998 or its brand name (Camzyos, Mavacamten). Reports on generic versions are filed under their own applications.

Reports

6,048

Serious

2,643

44% of reports

Hospitalization

1,161

Death reported

164

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue442
  • dyspnoea427
  • atrial fibrillation370
  • product dose omission issue362
  • dizziness353
  • product use issue268
  • off label use230
  • ejection fraction decreased224
  • therapy interrupted196
  • chest pain194
  • palpitations182
  • headache174
  • peripheral swelling171
  • nasopharyngitis153
  • weight increased150

Reports by year received

View as table
YearReports
2022390
2023825
20241,052
20251,458
20262,323

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,111 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ejection fraction decreasedSignal22450.844.710,743
atrial fibrillationSignal37013.312.04,185
therapy interruptedSignal1969.68.31,495
palpitationsSignal1825.44.7653
product use issueSignal2685.04.4851
product dose omission issueSignal3624.33.9920
peripheral swellingSignal1713.93.3362
chest painSignal1943.63.2373
nasopharyngitisSignal1532.92.5188
dyspnoeaSignal4272.62.4439
dizzinessSignal3532.52.2312
weight increasedSignal1502.32.0114
fatigue4422.01.8220
headache1741.00.80
off label use2300.90.82

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.